Abstract CT251: Savolitinib (savo) + Osimertinib (osi) Vs Savo + Placebo (PBO) in Patients (pts) with EGFR-mutated (egfrm), MET-amplified Advanced NSCLC with Progression on Osi
Cancer Research(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Cancer Research(2024)